Medtronic plc logo

Medtronic plc (MDT)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
101. 36
-0.63
-0.62%
After Hours
$
101. 87
+0.51 +0.5%
134.71B Market Cap
25.14 P/E Ratio
2.76% Div Yield
4,985,827 Volume
5.2 Eps
$ 101.99
Previous Close
Day Range
101.32 102.46
Year Range
79.29 106.33
Want to track MDT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 74 days
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know

Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know

Medtronic (MDT) closed at $90.19 in the latest trading session, marking a +1.05% move from the prior day.

Zacks | 10 months ago
Medtronic appoints Renault's exec Thierry Piéton as finance chief

Medtronic appoints Renault's exec Thierry Piéton as finance chief

Medtronic said on Monday it will appoint Renault's finance chief Thierry Piéton as its Chief Financial Officer, effective March 3.

Reuters | 10 months ago
Here's Why Medtronic (MDT) Gained But Lagged the Market Today

Here's Why Medtronic (MDT) Gained But Lagged the Market Today

Medtronic (MDT) concluded the recent trading session at $85.40, signifying a +0.18% move from its prior day's close.

Zacks | 10 months ago
Medtronic plc (MDT) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Medtronic plc (MDT) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Medtronic plc (NYSE:MDT ) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 5:15 PM ET Company Participants Geoff Martha - Chief Executive Officer Sean Salmon - EVP & President, Cardiovascular Portfolio Gary Corona - Interim Chief Financial Officer Que Dallara - EVP & President, Diabetes Operating Unit Conference Call Participants Robbie Marcus - JPMorgan Robbie Marcus Good afternoon, everyone.

Seekingalpha | 10 months ago
2 MedTech Stocks That Are Screaming Buys in January

2 MedTech Stocks That Are Screaming Buys in January

At the intersection of healthcare and technology, medtech companies are leveraging innovative solutions to improve patient care and health outcomes. Industry leaders are well-positioned to deliver shareholder value by addressing the growing healthcare demands of an aging global population and the rising prevalence of chronic diseases.

Fool | 10 months ago
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product

J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product

Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system. The post J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product appeared first on Investor's Business Daily.

Investors | 11 months ago
Is Medtronic's Dividend Safe?

Is Medtronic's Dividend Safe?

For not just years but decades, Medtronic (MDT 0.04%) has proven to be a reliable dividend growth stock to own. The medical device maker has been increasing its payout regularly, and with a yield of more than 3%, it pays more than twice what the S&P 500 averages (1.3%).

Fool | 11 months ago
1 Growth Stock Down 6% to Buy Right Now

1 Growth Stock Down 6% to Buy Right Now

You can break the stock market into different components, such as investing styles. These are growth and value stocks.

Fool | 11 months ago
Medtronic: Scoop Up This Dividend Aristocrat On Sale Now

Medtronic: Scoop Up This Dividend Aristocrat On Sale Now

Shares of Medtronic have lagged the S&P 500 index in the months since my previous article. The company's revenue and non-GAAP EPS grew during its fiscal Q2. Medtronic boasts an A credit rating from S&P on a stable outlook.

Seekingalpha | 11 months ago
Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division

Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division

Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeries Kuros will work collaboratively to sell, market and provide support services to Medtronic's sales force Kuros will keep responsibility for contracts, hospital partnerships and the recognition of revenue from sales Kuros will continue to sell directly in non-contracted territories as well as in markets outside of spine This agreement transforms an initial trial agreement into a strategic alliance SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 7, 2025 / Kuros Biosciences USA Inc., ("Kuros"), a wholly owned subsidiary of Kuros Biosciences AG, a global leader in advanced musculoskeletal bone healing technologies, today announced a strategic five-year, exclusive sales agency agreement with Medtronic, a leading global healthcare technology company. The agreement provides Medtronic with exclusivity in certain spine geographies within the U.S. market, underscoring a shared commitment to expanding access to Kuros' pioneering MagnetOs bone grafting technology.

Accesswire | 11 months ago
Medtronic: A Dividend Aristocrat That's Poised To Pop

Medtronic: A Dividend Aristocrat That's Poised To Pop

Medtronic offers value and income potential with a 3.5% dividend yield, strong fundamentals, and 47 years of consecutive dividend increases. Despite recent share price underperformance, MDT shows solid revenue and EPS growth driven by innovation in high-growth healthcare segments. MDT's forward P/E ratio of 14.9 is well below its historical average, indicating potential for valuation upside.

Seekingalpha | 11 months ago
Here's Why Medtronic (MDT) Gained But Lagged the Market Today

Here's Why Medtronic (MDT) Gained But Lagged the Market Today

Medtronic (MDT) closed at $80.95 in the latest trading session, marking a +0.91% move from the prior day.

Zacks | 11 months ago
Loading...
Load More